MBX Biosciences, Inc.
MBX
$8.70
$0.070.81%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 2.87M | 2.26M | 2.27M | 1.87M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 19.61M | 16.66M | 13.31M | 10.95M | |
| Operating Income | -19.61M | -16.66M | -13.31M | -10.95M | |
| Income Before Tax | -18.14M | -15.86M | -12.34M | -10.16M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -18.14M | -15.86M | -12.34M | -10.16M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -18.14M | -15.86M | -12.34M | -10.16M | |
| EBIT | -19.61M | -16.66M | -13.31M | -10.95M | |
| EBITDA | -19.54M | -16.60M | -13.27M | -10.91M | |
| EPS Basic | -2.78 | -1.05 | -0.85 | -9.40 | |
| Normalized Basic EPS | -1.74 | -0.66 | -0.53 | -5.87 | |
| EPS Diluted | -2.78 | -1.05 | -0.85 | -9.40 | |
| Normalized Diluted EPS | -1.74 | -0.66 | -0.53 | -5.87 | |
| Average Basic Shares Outstanding | 6.52M | 15.11M | 14.46M | 1.08M | |
| Average Diluted Shares Outstanding | 6.52M | 15.11M | 14.46M | 1.08M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
